NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Hepatitis Weekly


Susan Hasty, Publisher
Table of Contents . . . May 11th, 2009
Non-Subscriber - Summaries Only
Related Areas: Other Issues in Hepatitis Weekly | Other Publications

Hepatitis - Researchers from University of Navarra detail new studies and findings in the area of hepatitis

Hepatitis B Virus - Research in the area of hepatitis B virus reported from Shandong University

Hepatitis B Virus - Studies from K. Dallmeier and co-researchers in the area of hepatitis B virus published

Hepatitis C Virus - Findings from M. Kita and co-authors broaden understanding of hepatitis C virus

Hepatitis C Virus - Findings from N. Nakamoto and co-authors broaden understanding of hepatitis C virus

Hepatitis C Virus - New findings from E. Babaylova and co-authors in the area of hepatitis C virus published

Hepatitis C Virus - New hepatitis C virus research reported from University of Washington, Medical Department

Hepatitis C Virus - New hepatitis C virus study findings recently were published by H. Li and co-researchers

Hepatitis C Virus - Recent findings in hepatitis C virus described by K.X. Chen and colleagues

Hepatitis C Virus - Reports from Hiroshima University highlight recent research in hepatitis C virus

Hepatitis C Virus - Reports summarize hepatitis C virus study results from Yale University

Hepatitis C Virus - Research findings from University of Erlangen, Medical Department update understanding of hepatitis C virus

Hepatitis C Virus - Research from Emory University, Emory Vaccine Center provides new data on hepatitis C virus

Hepatitis C Virus - Research from University of Alberta yields new findings on hepatitis C virus

Hepatitis C Virus - Researchers from Seoul National University publish findings in hepatitis C virus

Hepatitis C Virus - Studies from F.J. Eng et al have provided new data on hepatitis C virus

Hepatitis C Virus - Studies from University of Lyon provide new data on hepatitis C virus

Hepatitis C Virus - Studies from University of Rome reveal new findings on hepatitis C virus

Hepatocellular Cancer - Research on hepatocellular cancer discussed by scientists at University of Hong Kong

HIV/AIDS - Findings from N. Crumcianflone et al in HIV/AIDS reported

HIV/AIDS - Report summarizes HIV/AIDS study findings from University of Copenhagen

HIV/AIDS - Reports summarize HIV/AIDS study results from M.J. Russo and co-researchers

Life Sciences - Data from K. Tracy and colleagues advance knowledge in life sciences

Neuropathy - Data on neuropathy detailed by N. Kabbaj and co-authors

Hepatitis A Virus - Research on hepatitis A virus detailed by scientists at Centro de Investigacion en Alimentacion y Desarrollo

Acute Hepatitis - Research from Yonsei University yields new data on acute hepatitis

Hemolysis - Studies from A. Rana and colleagues reveal new findings on hemolysis

Hepatic Disease - New hepatic disease findings from Y.H. Tsai and co-researchers published

Avila Therapeutics, Inc. - Avila Presents Preclinical Data on a Novel, Orally-Available, Protease Inhibitor, AVL181, for Hepatitis C Infection at EASL 2009 Meeting

Duke University Medical Center - Added anti-viral improves response, halves duration of hepatitis C treatment

Dynavax Technologies Corporation - Dynavax Announces First Quarter 2009 Financial Results

Dynavax Technologies Corporation - Dynavax Presents Additional Phase 3 Data for HEPLISAV™ Hepatitis B Vaccine at EASL Medical Conference

Hepatitis C Virus - Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

Hepatitis C Virus - Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C

Hepatitis C Virus - InterMune Reports First Quarter 2009 Financial Results and Business Highlights

HIV/AIDS - ImQuest BioSciences and Arisyn Therapeutics Announce Strategic Partnership to Develop Infectious Disease and Cancer Drugs

Hoffmann-La Roche Inc. - Roche Women Honored as 2009 TWIN Awardees

Integrated Environmental Technologies, Ltd. - Integrated Environmental Technologies, Ltd. announces MRSA – Specific EPA Registration of EcaFlo® Excelyte®

Linnden Communications - Biolex presents Locteron US Phase 2a hepatitis C data at EASL

Nasopharyngeal Carcinoma - GeneNews to conduct joint project funded by MYR 5 million grant from Malaysian government

Patient Advocate Foundation - Report Finds an Alarming Number of Chronically Ill Patients - Over 93 Percent - Reporting Medical Debt Crisis Issues in 2008 Have Some Form of Insurance

Schering-Plough Corporation - Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver EASL Annual Meeting

SCYNEXIS, Inc. - SCYNEXIS’ SCY-635 Demonstrates Clinically Relevant Single-Agent Results in a Phase 1b Study in Adults with HCV

Vertex Pharmaceuticals Incorporated - Vertex Pharmaceuticals to Present Data at EASL Suggesting Telaprevir’s Potential for Use in a Broad Range of HCV Patients and Highlighting the Company’s Expanded STAT-C Portfolio

ZymoGenetics, Inc. - Bristol-Myers Squibb and ZymoGenetics Present Positive 4-week Results of PEG-Interferon lambda with Ribavirin in Hepatitis C



Return to Top of Page

-----------------------
PR Login